|
US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the …
Fort Mills Times … approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or … |
ASCO: Antibody Boosts Chemo in CLLMedPage TodayCHICAGO — Adding the novel anti-CD20 agent obinutuzumab to standard chemotherapy for older, sicker patients with chronic lymphocytic leukemia improves outcomes, possibly more so than adding rituximab (Rit…
|
US Food and Drug Administration Approves REVLIMID® (lenalidomide) for the …
National Post … approval was based on the results of MCL-001, a phase II, multi-center, single arm, open label study evaluating lenalidomide in 134 patients with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or … |
Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of …7thSpace Interactive (press release)The clinical importance of this finding lies in the potential for treatment with an anti-CD20 antibody, for instance Rituximab, in addition t…
Retinal vasculitis in two pediatric patients with systemic lupus erythematosus …7thSpace Interactive (press release)… first patient also presented with vitreous hemorrhage and later non-arteritic ischemic optic neuropathy. She was treated with panr…
|
CLVS Zooms To New High, FLML Gets Thumbs Up, SNTA Dives, STEM Grows
RTT News According to the trial results, 40% of Rituximab-refractory patients achieved a complete response and 100% of marginal zone lymphoma patients achieved a complete or partial response. TGTX closed Monday’s trading 2.34% down at $6.25. by RTT Staff … |
The IN VIVO Blog (blog) |
Under One Roof: Roche Talks Up In-House Advantages In Cancer
The IN VIVO Blog (blog) That’s what Roche is looking to do in hematology, moving from the rituximab base to new drugs like GA101. “We have a number of scenarios that can help us both extend the franchise and potentially replace and extend the franchise,” Roche Pharma COO … |
|
ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of …
The Herald | HeraldOnline.com “We are encouraged by the evidence of antitumor activity of IGN002 observed in pre-clinical studies in rituximab-resistant tumor models and are preparing for an IND filing for IGN002 in the second half of 2014.” About IGN002. IGN002, a fusion molecule … |
Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of …Wall Street JournalAn investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination wi…
Study Hints of Rituximab MS BenefitMedPage TodayAmong 25 patients with secondary progressive MS treated with rituximab, nine showed decreases in disability and 12 appeared to stabilize after receiving at least two cycles of rituximab given every 3 mont…